Renal transplantation in high immunological risk patients: A single-center experience

dc.authoridBora Uslu / 0000-0001-8464-0977
dc.authoridEryiğit Eren / 0000-0001-6705-4095
dc.authorscopusidBora Uslu / 23471199500
dc.authorscopusidEryiğit Eren / 57196573309
dc.authorwosidBora Uslu / AAX-5738-2020
dc.authorwosidEryiğit Eren / 57196573309
dc.contributor.authorAlpay, Nadir
dc.contributor.authorÖzcelik, Umit
dc.contributor.authorEren, Eryiğit
dc.contributor.authorUslu, Bora
dc.date.accessioned2020-08-30T20:06:35Z
dc.date.available2020-08-30T20:06:35Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description1st International Transplant Network Congress -- OCT 17-21, 2018 -- Antalya, TURKEYen_US
dc.description.abstractBackground. Renal transplantation (RT) in high-risk patients is increasingly performed due to an inadequate organ pool and increased rate of RT after a failed transplantation. Safety and prognosis of RT in such patients with high risk is an ongoing debate. Herein we aimed to present our single-center experience on RT of high-risk patients. Methods. A total of 89 consecutive RT patients were included into this study in a 10-month period. Patients were divided into 3 groups: the low-risk group (n = 47) with negative panel reactive antibody (PRA), medium-risk group (n = 18) with positive PRA but mean fluorescence intensity (MFI) <2000, and high-risk group (n = 24) with positive PRA and MFI >2000 or donor specific antibody (DSA) positivity. Groups were compared in terms of demographic features, serum creatinine levels, acute rejection rates, delayed graft function (DGF), and patient or graft loss. Results. Age of the recipients were similar between the groups. Desensitization (7% vs 11% vs 42%, respectively, in low-, medium-, and high-risk groups; P = .001), plasmapheresis (6% vs 11% vs 46%, respectively, P < .001), and rituximab treatments (0% vs 0% vs 25%, respectively, P < .001) were significantly more frequently performed in high-risk patients. Serum creatinine levels at 1 month and 6 months after RT were similar between the groups (P = .43 and P = .71, respectively). Rates of acute rejection (6% vs 6% vs 16%, respectively, P = .52) and DGF (9% vs 11% vs 29%, respectively, P = .15) were similar between the groups. Frequencies of loss of patient or graft were also similar (0% vs 6% vs 4%, P = .15). Conclusion. RT may be successfully performed in high-risk patients without an increase in the risk of acute rejection, DGF, or patient/graft loss.en_US
dc.identifier.citationAlpay, N., Ozcelik, U., Eren, E., & Uslu, B. (2019). Renal Transplantation in High Immunological Risk Patients: A Single-Center Experience. TRANSPLANTATION PROCEEDINGS, 51(7), 2298–2301. https://doi.org/10.1016/j.transproceed.2019.04.075en_US
dc.identifier.doi10.1016/j.transproceed.2019.04.075en_US
dc.identifier.endpage2301en_US
dc.identifier.issn0041-1345en_US
dc.identifier.issn1873-2623en_US
dc.identifier.issue7en_US
dc.identifier.pmid31405734en_US
dc.identifier.scopus2-s2.0-85070197610en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2298en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2019.04.075
dc.identifier.urihttps://hdl.handle.net/20.500.12713/564
dc.identifier.volume51en_US
dc.identifier.wosWOS:000487349900038en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorEren, Eryiğiten_US
dc.institutionauthorUslu, Boraen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleRenal transplantation in high immunological risk patients: A single-center experienceen_US
dc.typeConference Objecten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
H49.pdf
Boyut:
236.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text